Viatris | VTRS - Gross Profit On Sales

Stock Price
17.17
Daily Change
-0.22 -1.27%
Monthly
26.16%
Yearly
95.78%
Q2 Forecast
14.73

Viatris reported $1.38B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Celltrion KRW 46.98B 579.12B Dec/2025
Cspc Pharmaceutical CNY 4.01B 329.18M Dec/2025
Deva Holding AS TRY 1.32B 235.77M Sep/2023
Dianthus Therapeutics USD 284K 112K Dec/2025
Divis Laboratories Ltd INR 16.59B 2.05B Dec/2025
Kangmei Pharma CNY 270.29M 20.26M Sep/2025
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
Laboratorios Farma EUR 105.28M 177.08M Jun/2025
Medical Developments International AUD 7.35M 7.37M Jun/2025
Neuren Pharmaceuticals AUD 6.69M 6.37M Jun/2025
Organigram Holdings CAD 23.32M 8.52M Dec/2025
Pharma Mar EUR 39.24M 47.46M Mar/2026
Qiagen NV USD 325.27M 19.53M Dec/2025
Sartorius EUR 414.5M 18.3M Mar/2026
Sino Biopharmaceutical CNY 10.5B 2.53B Dec/2024
Tilray USD 57.47M 10.16M Jun/2025
Viatris USD 1.38B 229.9M Mar/2026
Zealand Pharma A/S 68.91M 19.35M Dec/2025
Zz Pientze Pharmaceu CNY 1.16B 860.2M Mar/2026